Detalles de la búsqueda
1.
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Int J Cancer;
154(5): 863-872, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37840339
2.
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Int J Cancer;
154(12): 2142-2150, 2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38447003
3.
Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.
Br J Cancer;
130(2): 233-241, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37996507
4.
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy.
Int J Cancer;
153(10): 1726-1733, 2023 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37455496
5.
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Int J Cancer;
153(1): 153-163, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36883420
6.
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
BMC Cancer;
23(1): 561, 2023 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37337155
7.
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Lancet;
398(10302): 759-771, 2021 08 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34454674
8.
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Gastric Cancer;
24(6): 1330-1340, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34363528
9.
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
BMC Cancer;
20(1): 503, 2020 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32487035
10.
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Lancet;
392(10142): 123-133, 2018 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880231
11.
T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker.
Int J Cancer;
140(11): 2535-2544, 2017 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27925177
12.
Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Gastric Cancer;
24(6): 1341, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34536168
13.
Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial.
JAMA Netw Open;
7(1): e2352830, 2024 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38261316
14.
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
J Clin Oncol;
42(4): 410-420, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37963317
15.
Cytogenetics of extramedullary manifestations in multiple myeloma.
Br J Haematol;
161(1): 87-94, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23368088
16.
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Eur J Cancer;
178: 37-48, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36399909
17.
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.
J Immunother Cancer;
11(6)2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37399357
18.
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Eur J Cancer;
190: 112955, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37454537
19.
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
J Clin Oncol;
41(16): 2975-2987, 2023 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37018649
20.
Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice.
Oncol Res Treat;
45(12): 752-763, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36310006